Search for: "United States v. Karst" Results 21 - 38 of 38
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Feb 2011, 3:53 pm by FDABlog HPM
  Under the so-called “waiver doctrine” of the “law-of-the-case doctrine,” an issue that a party could have raised in an earlier appeal in the case, but that was not raised, is barred from consideration (see United States v. [read post]
17 Jan 2011, 9:27 am by FDABlog HPM
  The MMA also amended the patent statute to provide that “courts of the United States shall, to the extent consistent with the Constitution, have subject matter jurisdiction in any action brought  . . . under [28 U.S.C. [read post]
2 Nov 2010, 11:11 pm by FDABlog HPM
Department of Justice (Solicitor General of the United States) filed its highly anticipated amicus brief in response to the U.S. [read post]
21 Jun 2010, 12:47 pm by FDABlog HPM
Solvay Pharms, Inc., 588 F.3d 1318 (11th Cir. 2009) and United States, ex rel. [read post]
2 Jun 2010, 12:42 pm by FDABlog HPM
Supreme Court recently invited the Solicitor General to express the views of the United States on the topic (see our previous post here). [read post]
13 Apr 2010, 1:16 pm by WIMS
At issue is whether the STB and the second respondent, the United States Fish and Wildlife Service (FWS), complied with their obligations under § 7 of the Endangered Species Act (ESA) to ensure that the proposed rail was "not likely to jeopardize the continued existence of any endangered species" before approving the exemption. 16 U.S.C. [read post]
12 Apr 2010, 7:23 pm by Keith Rizzardi
United States Department of Transportation, 452 F.3d 362 (5th Cir. 2006)(until final approval was granted on an application, there was “insufficient certainty about the facilities’ future construction and environmental consequences to include them in the cumulative impact calculus. [read post]